Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease

2021 ◽  
Author(s):  
Yu‐Jie Zhou ◽  
Feng Gao ◽  
Wen‐Yue Liu ◽  
Grace Lai‐Hung Wong ◽  
Sanjiv Mahadeva ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver ◽  
Asian Patients

scholarly journals Nonalcoholic Fatty Liver Disease: A New Frontier for Hepatology in Bangladesh and a Call for Action to Combat

2017 ◽  
Vol 35 (4) ◽  
pp. 184-191
Author(s):  
Shahinul Alam ◽  
M Motahar Hossain ◽  
Golam Azam ◽  
Golam Mustafa ◽  
Mahbubul Alam ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Socioeconomic Condition ◽  
Mortality And Morbidity ◽  
Nonalcoholic Fatty Liver

Nonalcoholic Fatty Liver Disease (NAFLD) is the condition where fat accumulates in liver without significant ingestion of alcohol. NAFLD has become one of the most common liver conditions throughout the world. At the dawn of the history of NAFLD it was thought that NAFLD is disease of obese individual but lean patients are increasingly detected to have NAFLD. It seems that insulin resistance is central to the pathogenesis of NAFLD. In addition, oxidative stress and cytokines are important contributing factors, resulting in steatosis and progressive liver damage in genetically susceptible individuals. NAFLD varies considerably by ethnic group and Bangladeshi ethnicity is an independent risk factor for NAFLD. Prevalence of NAFLD in general population of Bangladesh is 4 - 18.4 %, which jumps up to 49.8% in diabetic patients. With the changes in socioeconomic condition and life style, aetiology of chronic liver disease is drifting from infectious to noninfectious diseases and the contribution of NAFLD is progressively increasing. Hepatitis B and hepatitis C have been the leading causes of mortality and morbidity from chronic liver disease in Bangladesh. But with increase in awareness and mass vaccination against HBV, prevalence of both the diseases has been decreasing in the country. The most alarming feature is that there is a high prevalence of NASH among the NAFLD patients. NAFLD is emerging as the largest contributor of chronic liver disease in Bangladesh. This warrants the attention of health policy makers and clinicians to explore this frontier and combat it from right now.J Bangladesh Coll Phys Surg 2017; 35(4): 184-191

Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease

2018 ◽  
Vol 19 (17) ◽  
pp. 1903-1914 ◽  
Author(s):  
Emanuel Raschi ◽  
Arianna Mazzotti ◽  
Elisabetta Poluzzi ◽  
Fabrizio De Ponti ◽  
Giulio Marchesini
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver ◽  
Disease Focus

Effect of a novel potential probioticLactobacillus paracaseiJlus66 isolated from fermented milk on nonalcoholic fatty liver in rats

2017 ◽  
Vol 8 (12) ◽  
pp. 4539-4546 ◽  
Author(s):  
Haiqing Ye ◽  
Qian Li ◽  
Zhengzhe Zhang ◽  
Maocheng Sun ◽  
Changhui Zhao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Fermented Milk ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease worldwide.

scholarly journals Accuracy of non-invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver disease

2021 ◽  
Vol 20 ◽  
pp. 100229
Author(s):  
Humberto O. Galizzi ◽  
Claudia A. Couto ◽  
Daniela O.L. Taranto ◽  
Samuel I.O. Araújo ◽  
Eduardo G. Vilela
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Esophageal Varices ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver ◽  
Non Invasive

scholarly journals Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Camelia Cojocariu ◽  
Ana-Maria Singeap ◽  
Irina Girleanu ◽  
Stefan Chiriac ◽  
Cristina M. Muzica ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Liver Disease ◽  
Kidney Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Chronic Liver ◽  
Major Health Problem ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease has become the main concern of hepatologists around the world and the main research topic for identifying effective and safe therapy. Advances in the treatment of chronic viral hepatitis in recent years have opened the way towards reducing mortality in patients with chronic liver disease. This goal has not yet been reached, as the burden of chronic liver disease remains a future major health problem as the incidence of the nonalcoholic fatty liver disease continues to rise. The proportion of patients with liver cirrhosis and those with hepatocellular carcinoma due to nonalcoholic liver disease on the liver transplant waiting list has increased in the last years. The upward trend in the incidence and prevalence of the disease in recent decades raises concern over a possible global epidemic, especially as the disease is still underestimated and underdiagnosed. Chronic kidney disease presented an increase in incidence and prevalence during the last years, and it has been associated not only with increased morbidity and mortality but also with high costs for the health system. During the last decade, several studies have shown the association between nonalcoholic fatty disease and chronic kidney disease, two major worldwide health problems.

scholarly journals Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1915
Author(s):  
Sébastien Le Garf ◽  
Véronique Nègre ◽  
Rodolphe Anty ◽  
Philippe Gual
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Chronic Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Current Knowledge ◽  
Public Health Problem ◽  
Overweight And Obesity ◽  
Chronic Liver ◽  
Nonalcoholic Fatty Liver

Metabolic-associated fatty liver disease (MAFLD), previously called nonalcoholic fatty liver diseases (NAFLD), is one of the most important causes of chronic liver disease worldwide and will likely become the leading cause of end-stage liver disease in the decades ahead. MAFLD covers a continuum of liver diseases from fatty liver to nonalcoholic steatohepatitis (NASH), liver fibrosis/cirrhosis and hepatocellular cancer. Importantly, the growing incidence of overweight and obesity in childhood, 4% in 1975 to 18% in 2016, with persisting obesity complications into adulthood, is likely to be harmful by increasing the incidence of severe MAFLD at an earlier age. Currently, MAFLD is the leading form of chronic liver disease in children and adolescents, with a global prevalence of 3 to 10%, pointing out that early diagnosis is therefore crucial. In this review, we highlight the current knowledge concerning the epidemiology, risk factors and potential pathogenic mechanisms, as well as diagnostic and therapeutic approaches, of pediatric MAFLD.

Sign in / Sign up

Export Citation Format

Share Document